奥美拉唑治疗对反流性食管炎模型大鼠食管菌群构成的影响

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (3): 370-375.

奥美拉唑治疗对反流性食管炎模型大鼠食管菌群构成的影响

高峰^1*, 贾梦真², 孙玥¹

1.首都医科大学附属北京安贞医院消化内科, 北京 100029;
2.北京市顺义区医院消化内科, 北京 101300

收稿日期:2020-06-04 修回日期:2020-07-02 出版日期:2021-03-05 发布日期:2021-03-01
通讯作者: ^*gaofeng4321@sina.com
基金资助:
北京市医院管理中心科研培育计划中医项目(PZ2018004)

Effects of administration of omeprazole on the esophageal microbiota composition in rat model with reflux esophagitis

GAO Feng^1*, JIA Meng-zhen², SUN Yue¹

1. Department of Gastroenterology, Bejing Anzhen Hospital, Capital Medical University, Beijing 100029;
2. Department of Gastroenterology, the Hospital of Shunyi District of Beijing, Beijing 101300, China

Received:2020-06-04 Revised:2020-07-02 Online:2021-03-05 Published:2021-03-01
Contact: ^*gaofeng4321@sina.com

摘要/Abstract

摘要： 目的探讨质子泵抑制剂(PPI)治疗对反流性食管炎大鼠食管菌群构成的影响。方法采用幽门部分结扎及前胃完全结扎手术建立反流性食管炎大鼠模型。SD 大鼠随机分为假手术对照组、反流性食管炎对照组和质子泵抑制剂奥美拉唑治疗组;术后1周开始灌胃,灌胃2 周后处死大鼠获取食管黏膜组织2块,1块用于细菌16S rDNA基因测序,另1块用于病理检查。结果每组6只大鼠入选研究,假手术对照组、反流性食管炎对照组和质子泵抑制剂治疗组食管黏膜的属水平菌群构成检测如下:消化链球菌属(Peptostre-ptococcus )丰度值分别为2.5%±0.5%、1.7%±0.7%和1.9%±0.5%;螺杆菌属(Heliobacter)丰度值分别为1.5%±0.1%、1.0%±0.5%和1.2%±0.3%;苏黎世杆菌属(Turicibacter)丰度值分别为1.0%±0.2%、0.5%±0.2%和1.0%±0.4%(P＜0.05);反流性食管炎对照组的以上3组菌属丰度值明显低于假手术对照组(P＜0.05)。反流性食管炎对照组和质子泵抑制剂治疗组病理分级(轻/中/重)分别为0/4/2和5/1/0(P＜0.05)。结论反流性食管炎大鼠食管菌群构成发生改变,有益菌减少;灌服质子泵抑制剂奥美拉唑治疗后,食管黏膜损伤减轻,有益菌增加,菌群构成恢复正常。

关键词: 反流性食管炎, 质子泵抑制剂, 高通量DNA测序技术, 食管菌群

Abstract: Objective To investigate the effect of proton pump inhibitor (PPI) omeprazole on the composition of esophageal microbiota in rats with reflux esophagitis. Methods The rat model of reflux esophagitis was established by the method of pyloric partial ligation and complete anterior gastric ligation. Rats were randomly divided into sham operation control group, reflux esophagitis control group and PPI treatment group (omeprazole). One week after the operation, distilled water/omeprazole tablets were intragastric administration once a day and two pieces of lower esophageal mucosa were obtained 2 weeks later, one for bacteria 16S rDNA gene sequencing, and another for pathological examination. Results Six surviving rats in each group were selected. The abundance values of sham operation control, reflux esophagitis control and PPI treatment groups at the genus level were as follows:Peptostreptococcus 2.5%±0.5%, 1.7%±0.7% and 1.9%±0.5%; Helicobacter 1.5%±0.1%, 1.0%±0.5% and 1.2%±0.3%;Turicibacter 1.0%±0.2%, 0.5%±0.2% and 1.0%±0.4% (P＜0.05). The abundances of Peptostreptococcus, Helicobacter, and Turicibacterin the reflux esophagitis control group were signifi-cantly reduced than those in the sham operation control group. The pathological grades of reflux esophagitis (mild/moderate/severe) in reflux esophagitis control and PPI treatment groups were 0/4/2 and 5/1/0(P＜0.05). Conclusions There are moderate changes in the composition of esophageal microbiota in rats with reflux esophagitis,the proportion of beneficial bacteria reduced. After the treatment of PPI omeprazole, the esophageal mucosal injury is alleviated, the proportion of beneficial bacteria increased, and the composition of esophageal microbiota returns to normal.

Key words: reflux esophagitis, proton pump inhibitor, high-throughput DNA sequencing, esophageal microbiota

中图分类号:

R571

高峰, 贾梦真, 孙玥. 奥美拉唑治疗对反流性食管炎模型大鼠食管菌群构成的影响[J]. 基础医学与临床, 2021, 41(3): 370-375.

GAO Feng, JIA Meng-zhen, SUN Yue. Effects of administration of omeprazole on the esophageal microbiota composition in rat model with reflux esophagitis[J]. Basic & Clinical Medicine, 2021, 41(3): 370-375.

参考文献

[1] 陈旻湖, 侯晓华, 肖英莲, 等. 中华医学会消化病学分会. 2014年中国胃食管反流病专家共识意见[J]. 胃肠病学杂志, 2015, 20: 155-158.
[2] Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease[J]. Am J Gastroenterol, 2013, 108: 308-328.
[3] Di Pilato V,Freschi G,Ringressi MN,et al. The esophageal microbiota in health and disease[J]. Ann NY Acad Sci, 2016, 1381: 21-33.
[4] Park CH, Lee SK. Exploring esophageal microbiomes in esophageal diseases: a systematic review[J]. J Neurogastroenterol Motil, 2020, 26: 171-179.
[5] Sjöstedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis[J]. Aliment Pharmacol Ther, 2005, 22: 183-191.
[6] Nagahara A, Hojo M, Asaoka D, et al. A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan[J]. Scand J Gastroenterol, 2014, 49: 409-417.
[7] Hojo M, Asahara T, Nagahara A, et al. Gut microbiota composition before and after use of proton pump inhibitors[J]. Dig Dis Sci, 2018, 63: 2940-2949.
[8] Amir I, Konikoff FM, Oppenheim M, et al. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors[J]. Environ Microbiol, 2014, 16: 2905-2914.
[9] 余英, 高峰, 张杰. 反流性食管炎治疗效果与食管下段菌群构成变化的关系研究[J]. 首都医科大学学报, 2020, 41: 243-248.
[10] 赵伟, 孙国志. 不同种实验动物间用药量换算[J]. 畜牧兽医科技信息, 2010, 32: 52-53.
[11] 郑朝旭, 林伟斌, 余俊峰, 等. 反流性食管炎大鼠模型的制备:不同管径内支架支撑幽门及前胃结扎[J]. 中国组织工程研究与临床康复,2010,14:3705-3708.
[12] 中华医学会消化内镜学分会. 反流性食管炎诊断及治疗指南(2003年)[J]. 中华消化内镜杂志, 2004, 21: 221-222.
[13] 余英, 张杰, 高峰, 等. 反流性食管炎严重程度与食管黏膜菌群结构变化的关系初探[J]. 中国医药, 2019, 14: 1519-1523.
[14] Wang ZK, Yang YS. Upper gastrointestinal microbiota and digestive diseases[J]. World J Gastroenterol, 2013, 19: 1541-1550.
[15] Baghdadi J, Chaudhary N, Pei Z, et al. Microbiome, innate immunity, and esophageal adenocarcinoma[J]. Clin Lab Med, 2014, 34: 721-732.
[16] Modiano N, Gerson LB. Risk factors for the detection of Barrett's esophagus in patients with erosive esophagitis[J]. Gastrointest Endosc, 2009, 69: 1014-1020.
[17] Yu Y, Gao F, Chen X, et al. Changes in the distal esophageal microbiota in Chinese patients with reflux esophagitis[J]. J Dig Dis, 2019, 20: 18-24.
[18] Liu L, Gao H, Wang H, et al. Comparison of esophageal function tests to investigate the effect of Helicobacter pylori infection on gastroesophageal reflux disease (GERD)[J]. Med Sci Monit, 2018, 24: 4791-4797.
[19] Al-Bayati L, Nayeri Fasaei B, Merat S, et al. Longitu-dinal analyses of gut-associated bacterial microbiota in ulcerative colitis patients[J]. Arch Iran Med, 2018, 21: 578-584.
[20] Munyaka PM, Rabbi MF, Khafipour E, et al. Acute dextran sulfate sodium (DSS)-induced colitis promotes gut microbial dysbiosis in mice[J]. J Basic Microbiol, 2016, 56: 986-998.
[21] Lee SM, Kim N, Nam RH, et al. Gut microbiota and butyrate level changes associated with the long-term administration of proton pump inhibitors to old rats[J]. Sci Rep, 2019, 9: 6626. doi: 10.1038/s41598-019-43112-x.